Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
24321257
DOI
10.1016/j.urolonc.2013.09.011
PII: S1078-1439(13)00384-0
Knihovny.cz E-zdroje
- Klíčová slova
- prognosis, renal cell carcinoma, sorafenib, sunitinib, survival,
- MeSH
- cytokiny terapeutické užití MeSH
- dospělí MeSH
- fenylmočovinové sloučeniny aplikace a dávkování MeSH
- indoly aplikace a dávkování MeSH
- karcinom z renálních buněk farmakoterapie mortalita sekundární MeSH
- lidé středního věku MeSH
- lidé MeSH
- metastázy nádorů MeSH
- míra přežití MeSH
- nádory ledvin farmakoterapie mortalita patologie MeSH
- následné studie MeSH
- niacinamid aplikace a dávkování analogy a deriváty MeSH
- prognóza MeSH
- progrese nemoci MeSH
- protokoly protinádorové kombinované chemoterapie terapeutické užití MeSH
- pyrroly aplikace a dávkování MeSH
- retrospektivní studie MeSH
- senioři MeSH
- sorafenib MeSH
- staging nádorů MeSH
- sunitinib MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- cytokiny MeSH
- fenylmočovinové sloučeniny MeSH
- indoly MeSH
- niacinamid MeSH
- pyrroly MeSH
- sorafenib MeSH
- sunitinib MeSH
OBJECTIVES: The aim of this retrospective study was to analyze prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors (TKIs) sunitinib or sorafenib after progression on cytokine therapy. MATERIALS AND METHODS: A national database of patients treated with targeted agents was used as the data source. A total of 319 patients treated with sunitinib (n = 181) or sorafenib (n = 138) after progression on cytokine therapy were analyzed. RESULTS: Prognostic factors significantly associated with poor overall survival in a multivariable Cox model included the time from diagnosis to the start of treatment with TKIs<1 year, increased neutrophil counts, increased lactate dehydrogenase, and Eastern Oncology Cooperative Group performance status 2 or higher. The parameters showing statistically significant association with progression-free survival included time from diagnosis to the beginning of treatment with TKI<1 year, increased lactate dehydrogenase, and Eastern Oncology Cooperative Group performance status 2 or higher. We have also validated the International Metastatic Renal Cell Carcinoma Database Consortium prognostic model in our cohort of patients. CONCLUSION: We demonstrate that the International Database Consortium prognostic model performs well for European patients treated with TKIs, including sunitinib or sorafenib, after progression on cytokines and suggest that a reduction from original 6 down to 4 parameters is possible.
Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Brno Czech Republic
Department of Oncology University Hospital of Motol Charles University Prague Czech Republic
Institute of Biostatistics and Analyses Masaryk University Brno Czech Republic
Citace poskytuje Crossref.org
